Literature DB >> 27334111

Critical role of XBP1 in cancer signalling is regulated by PIN1.

Unbin Chae1, Sun-Ji Park2, Bokyung Kim1, Shou Wei3, Ju-Sik Min4, Jun-Hyeog Lee5, Se Hoon Park6, Ann-Hwee Lee7, Kun Ping Lu3, Dong-Seok Lee8, Sang-Hyun Min9.   

Abstract

XBP1 (X-box-binding protein 1) is activated in cancer and has a pivotal role in tumorigenesis and progression of human cancer. In particular, the XBP1 transcriptional regulatory network is well known to drive cancer development, but little is known about whether the stability of XBP1 is regulated and, if so, what controls the stability of XBP1. In the present study we show that PIN1 prolyl isomerase interacts with the active form of XBP1 (XBP1s) in a phosphorylation-dependent manner and promotes XBP1s-induced cell proliferation and transformation through the regulation of XBP1 stability. By contrast, depletion of Pin1 in cancer cells reduced XBP1s expression, which subsequently inhibits cell proliferation and transformation. Interestingly, XBP1s activates multiple oncogenic pathways including NF-κB (nuclear factor κB), AP1 (activator protein 1) and Myc, and down-regulates PIN1 transcription via a negative-feedback mechanism through p53 induction. Ultimately, reciprocal regulation of Pin1 and XBP1s is associated with the activation of oncogenic pathways, and the relationship of PIN1 and XBP1 may be an attractive target for novel therapy in cancers.
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  PIN1; XBP1; cancer; isomerase

Mesh:

Substances:

Year:  2016        PMID: 27334111     DOI: 10.1042/BCJ20160482

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  9 in total

1.  TLR-7 Stress Signaling in Differentiating and Mature Eosinophils Is Mediated by the Prolyl Isomerase Pin1.

Authors:  Zhong-Jian Shen; Jie Hu; Venkatesh Kashi; Yury A Bochkov; James E Gern; James S Malter
Journal:  J Immunol       Date:  2018-11-05       Impact factor: 5.422

2.  miR-512-3p Overcomes Resistance to Cisplatin in Retinoblastoma by Promoting Apoptosis Induced by Endoplasmic Reticulum Stress.

Authors:  Miao Kong; Yuanyuan Han; Yunhe Zhao; Hong Zhang
Journal:  Med Sci Monit       Date:  2020-07-09

3.  Low expression of miR-199 in hepatocellular carcinoma contributes to tumor cell hyper-proliferation by negatively suppressing XBP1.

Authors:  Zheng Lou; Yong-Qiang Gong; Xing Zhou; Guo-Huang Hu
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

Review 4.  Prolyl isomerase Pin1: a promoter of cancer and a target for therapy.

Authors:  Yang Chen; Ya-Ran Wu; Hong-Ying Yang; Xin-Zhe Li; Meng-Meng Jie; Chang-Jiang Hu; Yu-Yun Wu; Shi-Ming Yang; Ying-Bin Yang
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

5.  The oncogenic role of GNL3 in the progression and metastasis of osteosarcoma.

Authors:  Tianyou Li; Long Li; Xiangyu Wu; Kaixuan Tian; Yanzhou Wang
Journal:  Cancer Manag Res       Date:  2019-03-15       Impact factor: 3.989

6.  Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology.

Authors:  Xiaowen Liu; Zongliang Yue; Yimou Cao; Sawa Ito; Jake Y Chen; Huanmei Wu; Sophie Paczesny; Lauren Taylor; Qing Zhang; Sung W Choi; Samir Hanash
Journal:  JCO Precis Oncol       Date:  2019-05-23

Review 7.  MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?

Authors:  Tingting Zhang; Ningning Li; Chaoyang Sun; Yang Jin; Xia Sheng
Journal:  EMBO Mol Med       Date:  2020-04-20       Impact factor: 12.137

Review 8.  Roles of peptidyl-prolyl isomerase Pin1 in disease pathogenesis.

Authors:  Jingyi Li; Chunfen Mo; Yifan Guo; Bowen Zhang; Xiao Feng; Qiuyue Si; Xiaobo Wu; Zhe Zhao; Lixin Gong; Dan He; Jichun Shao
Journal:  Theranostics       Date:  2021-01-19       Impact factor: 11.556

Review 9.  Targeting Pin1 for Modulation of Cell Motility and Cancer Therapy.

Authors:  Hsiang-Hao Chuang; Yen-Yi Zhen; Yu-Chen Tsai; Cheng-Hao Chuang; Ming-Shyan Huang; Michael Hsiao; Chih-Jen Yang
Journal:  Biomedicines       Date:  2021-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.